CN1608650A - 一种治疗冠心病心绞痛的中药及其制备方法 - Google Patents
一种治疗冠心病心绞痛的中药及其制备方法 Download PDFInfo
- Publication number
- CN1608650A CN1608650A CNA2003101081385A CN200310108138A CN1608650A CN 1608650 A CN1608650 A CN 1608650A CN A2003101081385 A CNA2003101081385 A CN A2003101081385A CN 200310108138 A CN200310108138 A CN 200310108138A CN 1608650 A CN1608650 A CN 1608650A
- Authority
- CN
- China
- Prior art keywords
- medicine
- rhizoma
- angina pectoris
- present
- heart
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 130
- 206010002383 Angina Pectoris Diseases 0.000 title claims abstract description 37
- 208000029078 coronary artery disease Diseases 0.000 title abstract description 8
- 239000002775 capsule Substances 0.000 claims abstract description 53
- 230000000694 effects Effects 0.000 claims abstract description 36
- 238000002360 preparation method Methods 0.000 claims abstract description 24
- 241000218176 Corydalis Species 0.000 claims abstract description 18
- 239000008187 granular material Substances 0.000 claims abstract description 5
- 229940079593 drug Drugs 0.000 claims description 37
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 33
- 238000011282 treatment Methods 0.000 claims description 26
- 241000208340 Araliaceae Species 0.000 claims description 21
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims description 21
- 235000003140 Panax quinquefolius Nutrition 0.000 claims description 21
- 235000008434 ginseng Nutrition 0.000 claims description 21
- 239000010135 fructus aurantii immaturus Substances 0.000 claims description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
- 241000237636 Pheretima Species 0.000 claims description 12
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 claims description 10
- 239000000284 extract Substances 0.000 claims description 10
- 238000002156 mixing Methods 0.000 claims description 9
- 239000003921 oil Substances 0.000 claims description 9
- 239000000341 volatile oil Substances 0.000 claims description 9
- 239000000843 powder Substances 0.000 claims description 8
- 238000005516 engineering process Methods 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 7
- 239000007864 aqueous solution Substances 0.000 claims description 6
- 238000001035 drying Methods 0.000 claims description 6
- 239000007788 liquid Substances 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 5
- 239000000243 solution Substances 0.000 claims description 4
- 241000533849 Gleditsia Species 0.000 claims description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 3
- 238000004821 distillation Methods 0.000 claims description 3
- 239000000706 filtrate Substances 0.000 claims description 3
- 239000008101 lactose Substances 0.000 claims description 3
- 238000004321 preservation Methods 0.000 claims description 3
- 238000003825 pressing Methods 0.000 claims description 3
- 238000010992 reflux Methods 0.000 claims description 3
- 238000005303 weighing Methods 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 2
- 239000000796 flavoring agent Substances 0.000 claims description 2
- 235000019634 flavors Nutrition 0.000 claims description 2
- 239000002994 raw material Substances 0.000 claims description 2
- 238000011084 recovery Methods 0.000 claims description 2
- 230000006870 function Effects 0.000 abstract description 12
- 208000002193 Pain Diseases 0.000 abstract description 10
- 230000017531 blood circulation Effects 0.000 abstract description 10
- 230000036407 pain Effects 0.000 abstract description 9
- 230000001737 promoting effect Effects 0.000 abstract description 5
- 239000000463 material Substances 0.000 abstract description 2
- 231100000331 toxic Toxicity 0.000 abstract description 2
- 230000002588 toxic effect Effects 0.000 abstract description 2
- 244000001632 Acorus gramineus Species 0.000 abstract 1
- 235000013073 Acorus gramineus Nutrition 0.000 abstract 1
- 244000183685 Citrus aurantium Species 0.000 abstract 1
- 235000007716 Citrus aurantium Nutrition 0.000 abstract 1
- 240000007164 Salvia officinalis Species 0.000 abstract 1
- 235000005412 red sage Nutrition 0.000 abstract 1
- 230000036541 health Effects 0.000 description 50
- 239000009561 tongxinluo Substances 0.000 description 24
- HSUGRBWQSSZJOP-RTWAWAEBSA-N diltiazem Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 description 19
- 210000002216 heart Anatomy 0.000 description 17
- 206010061216 Infarction Diseases 0.000 description 16
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 16
- 230000007574 infarction Effects 0.000 description 16
- 238000012360 testing method Methods 0.000 description 16
- 229960004166 diltiazem Drugs 0.000 description 15
- 208000031225 myocardial ischemia Diseases 0.000 description 14
- 239000008280 blood Substances 0.000 description 13
- 210000004369 blood Anatomy 0.000 description 12
- 208000028867 ischemia Diseases 0.000 description 12
- 241000282472 Canis lupus familiaris Species 0.000 description 11
- 230000008859 change Effects 0.000 description 11
- 210000000038 chest Anatomy 0.000 description 10
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 9
- 229910052760 oxygen Inorganic materials 0.000 description 9
- 239000001301 oxygen Substances 0.000 description 9
- 102000002045 Endothelin Human genes 0.000 description 7
- 108050009340 Endothelin Proteins 0.000 description 7
- 102000019197 Superoxide Dismutase Human genes 0.000 description 7
- 108010012715 Superoxide dismutase Proteins 0.000 description 7
- ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 description 7
- 210000004165 myocardium Anatomy 0.000 description 7
- 102000004420 Creatine Kinase Human genes 0.000 description 6
- 108010042126 Creatine kinase Proteins 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 208000010125 myocardial infarction Diseases 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 210000000952 spleen Anatomy 0.000 description 6
- 108091006146 Channels Proteins 0.000 description 5
- 241000700159 Rattus Species 0.000 description 5
- 230000003213 activating effect Effects 0.000 description 5
- 238000013507 mapping Methods 0.000 description 5
- 230000036284 oxygen consumption Effects 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 210000003462 vein Anatomy 0.000 description 5
- FMNQRUKVXAQEAZ-JNRFBPFXSA-N (5z,8s,9r,10e,12s)-9,12-dihydroxy-8-[(1s)-1-hydroxy-3-oxopropyl]heptadeca-5,10-dienoic acid Chemical compound CCCCC[C@H](O)\C=C\[C@@H](O)[C@H]([C@@H](O)CC=O)C\C=C/CCCC(O)=O FMNQRUKVXAQEAZ-JNRFBPFXSA-N 0.000 description 4
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 4
- 239000000006 Nitroglycerin Substances 0.000 description 4
- XNRNNGPBEPRNAR-UHFFFAOYSA-N Thromboxane B2 Natural products CCCCCC(O)C=CC1OC(O)CC(O)C1CC=CCCCC(O)=O XNRNNGPBEPRNAR-UHFFFAOYSA-N 0.000 description 4
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 4
- 206010003119 arrhythmia Diseases 0.000 description 4
- 230000006793 arrhythmia Effects 0.000 description 4
- 238000002651 drug therapy Methods 0.000 description 4
- 238000004043 dyeing Methods 0.000 description 4
- 229960003711 glyceryl trinitrate Drugs 0.000 description 4
- 230000000302 ischemic effect Effects 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 230000002107 myocardial effect Effects 0.000 description 4
- 210000003516 pericardium Anatomy 0.000 description 4
- 230000002085 persistent effect Effects 0.000 description 4
- 210000002381 plasma Anatomy 0.000 description 4
- 239000000651 prodrug Substances 0.000 description 4
- 229940002612 prodrug Drugs 0.000 description 4
- 210000000115 thoracic cavity Anatomy 0.000 description 4
- KFGOFTHODYBSGM-IJCBKZNRSA-N 6-Keto-prostaglandin F1a Chemical compound CCCCC[C@H](O)C=C[C@H]1[C@H](O)C[C@H](O)[C@@H]1CC(=O)CCCCC(O)=O KFGOFTHODYBSGM-IJCBKZNRSA-N 0.000 description 3
- 206010000077 Abdominal mass Diseases 0.000 description 3
- 206010062717 Increased upper airway secretion Diseases 0.000 description 3
- 208000007536 Thrombosis Diseases 0.000 description 3
- 230000002526 effect on cardiovascular system Effects 0.000 description 3
- 230000003419 expectorant effect Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 206010016256 fatigue Diseases 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 208000026435 phlegm Diseases 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 210000001835 viscera Anatomy 0.000 description 3
- 238000010792 warming Methods 0.000 description 3
- 206010000060 Abdominal distension Diseases 0.000 description 2
- 101710088194 Dehydrogenase Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 206010063837 Reperfusion injury Diseases 0.000 description 2
- 206010040007 Sense of oppression Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 229940114079 arachidonic acid Drugs 0.000 description 2
- 235000021342 arachidonic acid Nutrition 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 239000007963 capsule composition Substances 0.000 description 2
- 229940126678 chinese medicines Drugs 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 210000004351 coronary vessel Anatomy 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 239000003172 expectorant agent Substances 0.000 description 2
- 201000005577 familial hyperlipidemia Diseases 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000008899 fufang danshen Substances 0.000 description 2
- 239000008563 guizhi decoction Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- MOYKHGMNXAOIAT-JGWLITMVSA-N isosorbide dinitrate Chemical compound [O-][N+](=O)O[C@H]1CO[C@@H]2[C@H](O[N+](=O)[O-])CO[C@@H]21 MOYKHGMNXAOIAT-JGWLITMVSA-N 0.000 description 2
- 230000003907 kidney function Effects 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 231100000957 no side effect Toxicity 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- 230000005622 photoelectricity Effects 0.000 description 2
- 230000002980 postoperative effect Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 229940093252 sorbitrate Drugs 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 231100000820 toxicity test Toxicity 0.000 description 2
- 238000009602 toxicology test Methods 0.000 description 2
- 210000003932 urinary bladder Anatomy 0.000 description 2
- ZGZLYKUHYXFIIO-UHFFFAOYSA-N 5-nitro-2h-tetrazole Chemical compound [O-][N+](=O)C=1N=NNN=1 ZGZLYKUHYXFIIO-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 206010012118 Defect conduction intraventricular Diseases 0.000 description 1
- 206010012374 Depressed mood Diseases 0.000 description 1
- 241001489978 Eupolyphaga Species 0.000 description 1
- 239000001116 FEMA 4028 Substances 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 241000237903 Hirudo Species 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 241000233855 Orchidaceae Species 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
- 206010034568 Peripheral coldness Diseases 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 241000131808 Scolopendra Species 0.000 description 1
- 241000522620 Scorpio Species 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 206010000891 acute myocardial infarction Diseases 0.000 description 1
- 230000001800 adrenalinergic effect Effects 0.000 description 1
- 239000000674 adrenergic antagonist Substances 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 238000009246 art therapy Methods 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 1
- 235000011175 beta-cyclodextrine Nutrition 0.000 description 1
- 229960004853 betadex Drugs 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 206010007625 cardiogenic shock Diseases 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 210000001168 carotid artery common Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 210000003748 coronary sinus Anatomy 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 239000009465 diaoxinxuekang Substances 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 230000002183 duodenal effect Effects 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 229940089161 ginsenoside Drugs 0.000 description 1
- 229930182494 ginsenoside Natural products 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000003601 intercostal effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 210000004731 jugular vein Anatomy 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 231100001252 long-term toxicity Toxicity 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000002398 materia medica Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 230000003680 myocardial damage Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 229960002275 pentobarbital sodium Drugs 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000036581 peripheral resistance Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 208000018299 prostration Diseases 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 208000037803 restenosis Diseases 0.000 description 1
- 230000000250 revascularization Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 239000009490 scorpio Substances 0.000 description 1
- 239000008354 sodium chloride injection Substances 0.000 description 1
- 238000012109 statistical procedure Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000002627 tracheal intubation Methods 0.000 description 1
- 238000004879 turbidimetry Methods 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 239000010365 xinkeshu Substances 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
Description
组别 n 显效 有效 无效 加重 有效率治疗组 150 102(68.00) 43(28.67) 5(3.33) 0 (96.67)对照组 62 15(24.19) 30(48.39) 17(27.42) 0 (72.58) |
组别 时间 NST(例) ∑ST(mm)(例) STmax(例) NT(例)治前 3.50±1.46(115) 2.61±1.76(115) 0.95±0.35(115) 3.50±1.46(78)治疗组治后 2.2±1.30(115)**Δ 1.01±1.13**Δ(115) 0.39±0.76**Δ(115)2.41±1.35**Δ(78)治前 3.67±1.56(41) 3.06±1.79(41) 0.97±0.37(41) 3.62±1.56(28)对照组治后 2.80±1.40*(41) 2.80±1.30*(41) 0.68±0.51Δ(41) 2.49±1.42*(28) |
Claims (13)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2003101081385A CN1267126C (zh) | 2003-10-24 | 2003-10-24 | 一种治疗冠心病心绞痛的中药及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2003101081385A CN1267126C (zh) | 2003-10-24 | 2003-10-24 | 一种治疗冠心病心绞痛的中药及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1608650A true CN1608650A (zh) | 2005-04-27 |
CN1267126C CN1267126C (zh) | 2006-08-02 |
Family
ID=34758474
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2003101081385A Expired - Fee Related CN1267126C (zh) | 2003-10-24 | 2003-10-24 | 一种治疗冠心病心绞痛的中药及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1267126C (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2431041A4 (en) * | 2009-05-15 | 2012-12-26 | Chengdu kanghong pharmaceutical co ltd | PHARMACEUTICAL COMPOSITION FOR TREATING CARDIOVASCULAR DISORDER AND USE THEREOF |
-
2003
- 2003-10-24 CN CNB2003101081385A patent/CN1267126C/zh not_active Expired - Fee Related
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2431041A4 (en) * | 2009-05-15 | 2012-12-26 | Chengdu kanghong pharmaceutical co ltd | PHARMACEUTICAL COMPOSITION FOR TREATING CARDIOVASCULAR DISORDER AND USE THEREOF |
Also Published As
Publication number | Publication date |
---|---|
CN1267126C (zh) | 2006-08-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1748765A (zh) | 一种具有通便排毒、减肥降脂功能的组合物及制备方法 | |
CN1245198C (zh) | 一种治疗糖尿病的中药组合物及其制备方法 | |
CN101049324A (zh) | 一种由银杏叶与葛根素制成的药物组合物 | |
CN1923241A (zh) | 包括淫羊藿提取物、钩藤提取物、天麻素的药物组合物及其制备方法和应用 | |
CN101041019A (zh) | 一种治疗冠心病的中药组合物及其制备方法 | |
CN1112439A (zh) | 治疗糖尿病的中药及其生产方法 | |
CN1608650A (zh) | 一种治疗冠心病心绞痛的中药及其制备方法 | |
CN1931233A (zh) | 一种用于治疗心脑血管疾病的丹参和淫羊藿的药用组合物 | |
CN1294936C (zh) | 一种治疗糖尿病的药物及其制备方法 | |
CN1296080C (zh) | 清肝降压胶囊及其制备方法 | |
CN1596939A (zh) | 一种治疗心脑血管疾病的中成药及其制备方法 | |
CN1864738A (zh) | 一种治疗冠心病心绞痛的药物 | |
CN101062027A (zh) | 牛磺酸和治疗心脑血管疾病的药物的组合物 | |
CN1541671A (zh) | 一种治疗心绞痛的药物及该药物的制备方法和应用 | |
CN101040886A (zh) | 灯盏花和丹参酮ⅱa磺酸钠的药用组合物 | |
CN101049355A (zh) | 一种由红花与山楂叶制成的药物组合物 | |
CN1726934A (zh) | 血府逐瘀药物组合物在制备降血脂药物中的应用 | |
CN1954870A (zh) | 一种由肿节风和白花蛇舌草制成的药物组合物 | |
CN1931216A (zh) | 一种由红花与红景天制成的药物组合物 | |
CN1287835C (zh) | 一种治疗冠心病、心绞痛的药物组合物及其制备方法 | |
CN1631895A (zh) | 苦杏仁苷的制备方法和苦杏仁苷在制备促进心脑胰及伤口血液循环的苦杏仁苷制剂中的应用 | |
CN1709439A (zh) | 一种参芪降糖滴丸及其制备检测方法 | |
CN1169569C (zh) | 治疗乳腺增生病的中药组合物及其制备方法 | |
CN1181089C (zh) | 黄姜素的制备方法和含有该成分的口服药物 | |
CN1903268A (zh) | 治疗动脉粥样硬化的药物组合物及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: SHANGHAI WANHETANG PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: SHANGHAI WANHE PHARMACEUTICAL INDUSTRY CO., LTD. Effective date: 20050701 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20050701 Address after: 200080 room 10, No. 299, Lane 504, Wuzhou Road, Shanghai Applicant after: Shanghai Wanhe Pharmaceutical Industry Co., Ltd. Address before: 200080 room 7, No. 299, Lane 301, Wuzhou Road, Shanghai Applicant before: Shanghai Wanhe Pharmaceutical Industry Co., Ltd. |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
DD01 | Delivery of document by public notice | ||
DD01 | Delivery of document by public notice |
Addressee: Shanghai Wanhe Pharmaceutical Industry Co., Ltd. Document name: Notification to Pay the Fees |
|
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20060802 Termination date: 20181024 |